Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials

Bahman Amani, View ORCID ProfileAhmad Khanijahani, Behnam Amani
doi: https://doi.org/10.1101/2020.06.05.20122705
Bahman Amani
1School of Public Health, Tehran University of Medical Sciences, Poursina St, Ghods St. Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmad Khanijahani
2School of Health Sciences, Duquesne University, 600 Forbes Ave, Pittsburgh, PA 15282
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmad Khanijahani
Behnam Amani
1School of Public Health, Tehran University of Medical Sciences, Poursina St, Ghods St. Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: b_amani@alumnus.tums.ac.ir
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background & Objective The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease COVID-19 pandemic is disputed. This study aimed to examine the efficacy and safety of HCQ plus the standard of care in COVID-19 patients.

Methods PubMed, The Cochrane Library, Embase, and web of sciences were searched up to June 1, 2020. The references list of the key studies was reviewed for additional relevant resources. Clinical studies registry databases were searched for identifying potential clinical trials. The quality of the included studies was evaluated using the Cochrane Collaboration’s tool. Meta-analysis was performed using RevMan software (version 5.3).

Results Three randomized controlled trials with total number of 242 patients were identified eligible for meta-analysis. No significant differences were observed between HCQ and standard care in terms of viral clearance (Risk ratio [RR] = 1.03; 95% confidence interval [CI] = 0.91, 1.16; P = 0.68), disease progression (RR = 0.92; 95% CI = 0.10, 0.81; P = 0.94), Chest CT (RR = 1.40; 95% CI = 1.03, 1.91; P = 0.03). There is a significant difference between HCQ and standard care for adverse events (RR = 2.88; 95% CI = 1.50, 5.54; P = 0.002).

Conclusion Although the current meta-analysis failed to confirm the efficacy and safety of HCQ in the treatment of COVID-19 patients, further rigorous randomized clinical trials are necessary to evaluate conclusively the efficacy and safety of HCQ against COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was obtained for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are openly available at: Chen, Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv (2020). Tang, W. et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv (2020). Chen, J. et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science) 49, 0-0 (2020).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 12, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials
Bahman Amani, Ahmad Khanijahani, Behnam Amani
medRxiv 2020.06.05.20122705; doi: https://doi.org/10.1101/2020.06.05.20122705
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials
Bahman Amani, Ahmad Khanijahani, Behnam Amani
medRxiv 2020.06.05.20122705; doi: https://doi.org/10.1101/2020.06.05.20122705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (141)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4809)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5280)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (767)
  • Public and Global Health (1796)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)